These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29504094)

  • 1. Specificity of Good Manufacturing Practice (GMP) for Biomedical Cell Products.
    Tulina MA; Pyatigorskaya NV
    Bull Exp Biol Med; 2018 Mar; 164(4):579-582. PubMed ID: 29504094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Draft of Iranian National Guideline for Cell Therapy Manufacturing.
    Aghayan HR; Arjmand B; Ahmadbeigi N; Gheisari Y; Vasei M
    Arch Iran Med; 2017 Aug; 20(8):547-550. PubMed ID: 28846019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Media fill for validation of a good manufacturing practice-compliant cell production process.
    Serra M; Roseti L; Bassi A
    Methods Mol Biol; 2015; 1283():161-9. PubMed ID: 25096172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GMP-compliant human adipose tissue-derived mesenchymal stem cells for cellular therapy.
    Aghayan HR; Goodarzi P; Arjmand B
    Methods Mol Biol; 2015; 1283():93-107. PubMed ID: 25138723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience.
    Gee AP; Richman S; Durett A; McKenna D; Traverse J; Henry T; Fisk D; Pepine C; Bloom J; Willerson J; Prater K; Zhao D; Koç JR; Ellis S; Taylor D; Cogle C; Moyé L; Simari R; Skarlatos S
    Cytotherapy; 2010 Sep; 12(5):684-91. PubMed ID: 20524773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GMP-conformant on-site manufacturing of a CD133
    Skorska A; Müller P; Gaebel R; Große J; Lemcke H; Lux CA; Bastian M; Hausburg F; Zarniko N; Bubritzki S; Ruch U; Tiedemann G; David R; Steinhoff G
    Stem Cell Res Ther; 2017 Feb; 8(1):33. PubMed ID: 28187777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioprocessing automation in cell therapy manufacturing: Outcomes of special interest group automation workshop.
    Ball O; Robinson S; Bure K; Brindley DA; Mccall D
    Cytotherapy; 2018 Apr; 20(4):592-599. PubMed ID: 29452894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automation of cellular therapy product manufacturing: results of a split validation comparing CD34 selection of peripheral blood stem cell apheresis product with a semi-manual vs. an automatic procedure.
    Hümmer C; Poppe C; Bunos M; Stock B; Wingenfeld E; Huppert V; Stuth J; Reck K; Essl M; Seifried E; Bonig H
    J Transl Med; 2016 Mar; 14():76. PubMed ID: 26983643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [International approaches to the regulation of cell therapy products].
    Piatigorskaia NV; Tulina MA; Aladysheva ZhI; Beregovykh VV
    Vestn Ross Akad Med Nauk; 2013; (8):4-8. PubMed ID: 24340637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concise review: mind the gap: challenges in characterizing and quantifying cell- and tissue-based therapies for clinical translation.
    Rayment EA; Williams DJ
    Stem Cells; 2010 May; 28(5):996-1004. PubMed ID: 20333747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards Automated Manufacturing for Cell Therapies.
    Smith D; Heathman TRJ; Klarer A; LeBlon C; Tada Y; Hampson B
    Curr Hematol Malig Rep; 2019 Aug; 14(4):278-285. PubMed ID: 31254154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality Assessment and Production of Human Cells for Clinical Use.
    Fraser L; Bruce K; Campbell JM; De Sousa PA
    Methods Mol Biol; 2018; 1780():607-629. PubMed ID: 29856038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Good Manufacturing Practice (GMP) Translation of Advanced Cellular Therapeutics: Lessons for the Manufacture of Erythrocytes as Medicinal Products.
    McGowan NWA; Campbell JDM; Mountford JC
    Methods Mol Biol; 2018; 1698():285-292. PubMed ID: 29076098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standard operating procedure for the good manufacturing practice-compliant production of human bone marrow mesenchymal stem cells.
    Roseti L; Serra M; Bassi A
    Methods Mol Biol; 2015; 1283():171-86. PubMed ID: 25092055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic cell therapy manufacturing: process development technologies and facility design options.
    Abbasalizadeh S; Pakzad M; Cabral JMS; Baharvand H
    Expert Opin Biol Ther; 2017 Oct; 17(10):1201-1219. PubMed ID: 28699788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in processing systems for cell and tissue cultures toward therapeutic application.
    Kino-oka M; Taya M
    J Biosci Bioeng; 2009 Oct; 108(4):267-76. PubMed ID: 19716513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality Standards of Stem Cell Sources for Clinical Treatment of Neurodegenerative Diseases.
    Han F; Gu Y; Zhao H; Chen L
    Adv Exp Med Biol; 2020; 1266():9-19. PubMed ID: 33105492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and production of good manufacturing practice grade human embryonic stem cell lines as source material for clinical application.
    De Sousa PA; Downie JM; Tye BJ; Bruce K; Dand P; Dhanjal S; Serhal P; Harper J; Turner M; Bateman M
    Stem Cell Res; 2016 Sep; 17(2):379-390. PubMed ID: 27639108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivation of GMP-compliant integration-free hiPSCs using modified mRNAs.
    Durruthy JD; Sebastiano V
    Methods Mol Biol; 2015; 1283():31-42. PubMed ID: 25304205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Process validation.
    Preti RA
    Cytotherapy; 1999; 1(6):481-3. PubMed ID: 20426548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.